Literature DB >> 24578446

Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis.

Grant E Sara1, Philip M Burgess1, Gin S Malhi1, Harvey A Whiteford1, Wayne C Hall1.   

Abstract

BACKGROUND: Few studies have examined the impact of stimulant use on outcome in early psychosis. Ceasing substance use may lead to positive outcomes in psychosis. AIMS: To examine whether baseline cannabis or stimulant disorders and ongoing drug use predict readmission within 2 years of a first psychosis admission.
METHOD: Predictors of readmission were examined with Cox regression in 7269 people aged 15-29 years with a first psychosis admission.
RESULTS: Baseline cannabis and stimulant disorders did not predict readmission. A stimulant disorder diagnosis prior to index psychosis admission predicted readmission, but a prior cannabis disorder diagnosis did not. Ongoing problem drug use predicted readmission. The lowest rate of readmission occurred in people whose baseline drug problems were discontinued.
CONCLUSIONS: Prior admissions with stimulant disorder may be a negative prognostic sign in first-episode psychosis. Drug use diagnoses at baseline may be a good prognostic sign if they are identified and controlled. Royal College of Psychiatrists.

Entities:  

Mesh:

Year:  2014        PMID: 24578446     DOI: 10.1192/bjp.bp.113.135145

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  2 in total

1.  Analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015.

Authors:  Sang-Uk Lee; Minah Soh; Vin Ryu; Chul-Eung Kim; Subin Park; Sungwon Roh; In-Hwan Oh; Hye-Young Lee; SungKu Choi
Journal:  Int J Ment Health Syst       Date:  2018-03-02

2.  Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Benjamin Murrie; Julia Lappin; Matthew Large; Grant Sara
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.